| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/13/2011 | US20110008333 Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| 01/13/2011 | US20110008331 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| 01/13/2011 | US20110008320 Further Use of Protein Kinase N Beta |
| 01/13/2011 | US20110008316 Biological bioadhesive compositions and methods of preparation and use |
| 01/13/2011 | US20110008315 Recombinant elastase proteins and methods of manufacturing and use thereof |
| 01/13/2011 | US20110008314 Methods of and compositions for inhibiting the proliferation of mammalian cells |
| 01/13/2011 | US20110008313 tPA MUTANT IN THE TREATMENT OF ACUTE BRAIN INJURY AND NEURODEGENERATIVE DISORDERS |
| 01/13/2011 | US20110008312 Radical therapeutic agent for keloid and hypertrophic scar |
| 01/13/2011 | US20110008311 Animal Model and Use of 17Beta-Hydroxysteroid Dehydrogenase Type 7 in the Diagnosis of Anencephaly |
| 01/13/2011 | US20110008310 Methods and compositions for mitochondrial replacement therapy |
| 01/13/2011 | US20110008309 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| 01/13/2011 | US20110008308 Composition for hair, skin, nails |
| 01/13/2011 | US20110008307 Cephalotaxine Alkaloid Compositions and Uses Thereof |
| 01/13/2011 | US20110008304 Use of cells to facilitate targeted delivery of nanoparticle therapies |
| 01/13/2011 | US20110008297 Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
| 01/13/2011 | US20110008295 Simian adenoviruses sadv-36, -42.1, -42.2, and -44 and uses thereof |
| 01/13/2011 | US20110008293 Device and method for preparing microparticles |
| 01/13/2011 | US20110008291 Use of antifungal compositions to treat upper gastrointestinal conditions |
| 01/13/2011 | US20110008290 Method for predicting the therapeutic responsiveness of patients to a medical treatment with an interferon |
| 01/13/2011 | US20110008289 Hyperglycosylated polypeptide variants and methods of use |
| 01/13/2011 | US20110008288 Hepatitis c virus inhibitors |
| 01/13/2011 | US20110008287 Methods and means for the treatment of hpv induced intraepithelial neoplasias |
| 01/13/2011 | US20110008286 Novel proline substituted cyclosporin analogues |
| 01/13/2011 | US20110008285 Novel cyclosporin analogues |
| 01/13/2011 | US20110008284 Novel clyclosporin analogues |
| 01/13/2011 | US20110008283 Interferon fusion proteins |
| 01/13/2011 | US20110008282 IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
| 01/13/2011 | US20110008281 Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia |
| 01/13/2011 | US20110008280 Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| 01/13/2011 | US20110008279 Methods and Compositions Relating to Adhesins as Adjuvants |
| 01/13/2011 | US20110008278 Modulators of paraptosis and related methods |
| 01/13/2011 | US20110008269 Compositions and Methods Which Modulate G-Protein Signaling for the Treatment of Inflammatory Disorders such as Asthma and Allergic Conjunctivitis |
| 01/13/2011 | US20110008251 Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses |
| 01/13/2011 | US20110008248 Peptide Antagonists of TGF-Beta Family Members and Therapeutic Uses Thereof |
| 01/13/2011 | DE202010009512U1 Collagenpulver Collagen powder |
| 01/13/2011 | DE102009032179A1 Verfahren zur Reinigung von Interferon beta A process for purifying interferon beta |
| 01/13/2011 | CA2804602A1 Codon-optimized factor viii variants and synthetic liver-specific promoter |
| 01/13/2011 | CA2767711A1 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| 01/13/2011 | CA2767612A1 Variants of plasminogen and plasmin |
| 01/13/2011 | CA2767595A1 Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof |
| 01/13/2011 | CA2767503A1 Long-acting coagulation factors and methods of producing same |
| 01/13/2011 | CA2766649A1 Zinc supplementation to increase responsiveness to metalloprotease therapy |
| 01/13/2011 | CA2766008A1 Composition for the treatment of benign prostate hyperplasia |
| 01/13/2011 | CA2765157A1 Method of treating age related disorders |
| 01/13/2011 | CA2764792A1 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition |
| 01/13/2011 | CA2761967A1 Skin repair compositions comprising circadian gene activators and a synergistic combination of sirt1 gene activators |
| 01/12/2011 | EP2272985A1 Antisense modulation of apolipoprotein (A) expression |
| 01/12/2011 | EP2272960A1 Human protein NELL2 gene |
| 01/12/2011 | EP2272959A1 BMP-11 compositions |
| 01/12/2011 | EP2272958A1 Modulation of forkhead box O1A expression |
| 01/12/2011 | EP2272957A2 Bitter taste receptors |
| 01/12/2011 | EP2272951A1 Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
| 01/12/2011 | EP2272947A1 Peptide conjugated anti-cancer prodrugs |
| 01/12/2011 | EP2272875A1 Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof |
| 01/12/2011 | EP2272868A2 Combination therapy for B cell disorders |
| 01/12/2011 | EP2272866A2 Therapeutically active alpha-MSH analogues |
| 01/12/2011 | EP2272865A2 Method of producing hydroxyalkyl starch derivatives |
| 01/12/2011 | EP2272864A2 Binding agents which inhibit myostatin |
| 01/12/2011 | EP2272861A1 Polyepitope carrier protein |
| 01/12/2011 | EP2272859A2 Immunological herpes simplex virus antigens and methods for use thereof |
| 01/12/2011 | EP2272858A2 HCV inhibitors comprising beta amino acids and their uses |
| 01/12/2011 | EP2272565A2 Prevention of thrombus formation and/or stabilization |
| 01/12/2011 | EP2272539A2 Truncated fragments of alpha-synuclein in lewy body disease |
| 01/12/2011 | EP2272535A1 The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 01/12/2011 | EP2272533A1 Soluble FcyR fusion proteins and methods of use thereof |
| 01/12/2011 | EP2272529A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272528A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272527A2 Combined DNA vaccine and biological modifiers for cancer therapy |
| 01/12/2011 | EP2272524A2 Y2 selective receptor agonists for therapeutic interventions |
| 01/12/2011 | EP2272515A1 Novel uses of sodium 4-phenylbutyrate (4 pba) and the pharmaceutically acceptable salts thereof |
| 01/12/2011 | EP2272508A2 Pharmaceutical Formulations for Dry Powder Inhalers |
| 01/12/2011 | EP2272501A1 Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate |
| 01/12/2011 | EP2272497A2 Methods Of Increasing Lymphatic Function |
| 01/12/2011 | EP2272340A1 Botulinum toxin |
| 01/12/2011 | EP2271750A1 Uricase compositions and methods of use |
| 01/12/2011 | EP2271665A1 Highly bridged peptides from actinomadura namibiensis |
| 01/12/2011 | EP2271661A2 Compounds derived from muramyldipeptide |
| 01/12/2011 | EP2271370A2 Compositions and methods for diagnosing and treating melanoma |
| 01/12/2011 | EP2271369A1 Novel therapeutical tools and methods for treating blindness |
| 01/12/2011 | EP2271363A1 Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase |
| 01/12/2011 | EP2271358A2 Neurodegenerative disorders |
| 01/12/2011 | EP2271357A2 Cosmetic use of annexin ii-type proteins for treating dryness of the skin |
| 01/12/2011 | EP2271356A1 Novel antimicrobial peptides |
| 01/12/2011 | EP2271355A2 Use of prokaryotic tir-domain containing proteins as therapeutic and diagnostic agents |
| 01/12/2011 | EP2271352A1 Compositions and methods for treatment of neoplastic disease |
| 01/12/2011 | EP2271337A1 Beta-turn peptidomimetic cyclic compounds for treating dry eye |
| 01/12/2011 | EP2271314A2 Compositions and methods for the preparation of nanoemulsions |
| 01/12/2011 | EP2271312A2 Nerve repair with a hydrogel and optional adhesive |
| 01/12/2011 | EP2271213A1 Methods for treating a condition characterized by dysfunction in protein homeostasis |
| 01/12/2011 | EP1827471B1 Composition and method for increasing apoptosis in cancer cells |
| 01/12/2011 | EP1814904B1 Antibiotic drosocin derivatives |
| 01/12/2011 | EP1797110B1 Antibacterial amide macrocycles iv |
| 01/12/2011 | EP1730167B1 Macrocyclic peptides active against the hepatitis c virus |
| 01/12/2011 | EP1660524B1 Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases |
| 01/12/2011 | EP1638522B1 Solid drug formulation and device for storage and controlled delivery thereof |
| 01/12/2011 | EP1613341B1 Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction |
| 01/12/2011 | EP1583541B1 Compounds and methods for increasing neurogenesis |
| 01/12/2011 | EP1470224B1 Molecular libraries |
| 01/12/2011 | EP1465927B1 Bag3 antibodies to be used in research, diagnostics and therapy for cell death-involving diseases |
| 01/12/2011 | EP1439863B1 Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism |